Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study

The introduction of the so-called immune checkpoint inhibitors (ICIs) substantially changed the history of cancer therapy. On the other hand, they can induce the development of rheumatic immune-related adverse events (Rh-irAEs). In the scenario of a joint oncology/rheumatology outpatient clinic, we...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Fulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, Giulio Olivieri, Alessio Cirillo, Alain Gelibter, Vincenzo Picone, Andrea Botticelli, Fabrizio Conti
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2023-03-01
Цуврал:	Life
Нөхцлүүд:	immune checkpoint inhibitors rheumatic diseases systemic autoimmune diseases
Онлайн хандалт:	https://www.mdpi.com/2075-1729/13/4/877
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!